Induction of bovine leukaemia virus Env-specific Th-1 type immunity in mice by vaccination with short synthesized peptide-liposome

Vaccine

Volumn 14, Issue 12, 1996, Pages 1143-1148

  Ohishi, Kazue ^a   Kabeya, Hidenori ^b   Amanuma, Hiroshi ^a   Onuma, Misao ^b  

^a RIKEN   (Japan)

^b HOKKAIDO UNIVERSITY   (Japan)

Author keywords

Bovine leukaemia virus; Liposome; Peptide antigen; Th 1 type immunity

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 2; LIPOSOME; SYNTHETIC PEPTIDE; VIRUS VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BOVINE LEUKEMIA VIRUS; CELLULAR IMMUNITY; CONTROLLED STUDY; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

EID: 0030581390     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/0264-410X(96)00033-3     Document Type: Article

References (28)

1. 1 Mammerickx, M., Palm, R., Portetelle, D. and Burny, A. Experimental transmission of enzootic bovine leukosis to sheep: latency period of the tumoral disease. Leukemia 1988, 2, 103-107
2. 2 Miller, J.M. and Van der Maaten, M.J. Evaluation of an inactivated bovine leukemia virus preparation as an immunogen in cattle. Ann. Rech. Vet. 1978, 9, 871-877
3. 3 Onuma, M., Hodatsu, T., Yamamoto, S. et al. Protection by vaccination against bovine leukemia virus infection in sheep. Am. J. Vet. Res. 1984, 45, 1212-1215
4. 4 Kono, Y., Arai, K., Sentsui, H., Matsukawa, S. and Itohara, S. Protection against bovine leukemia virus infection in sheep by active and passive immunization. Jpn. J. Vet. Res. 1986, 48, 117-125
5. 5 Ohishi, K., Suzuki, H., Yamamoto, T. et al. Protective immunity against bovine leukaemia virus (BLV) induced in carrier sheep by inoculation with vaccinia-BLV env recombinant: association with cell-mediated immunity. J. Gen. Virol. 1991, 72, 1887-1892
6. 6 Gatei, M.H., Naif, H.M., Kumar, S. et al. Protection of sheep against bovine leukemia virus (BLV) infection by vaccination with recombinant vaccinia viruses expressing BLV envelope glycoprotein: correlation of protection with CD4 T-cell response to gp51 peptide 51-70. J. Virol. 1993, 67, 1803-1810
7. 7 Ohishi, K., Suzuki, H., Yasutomi, Y. et al. Augmentation of bovine leukemia virus (BLV)-specific lymphocyte proliferation responses in ruminants by inoculation with BLV env-recombinant vaccinia virus: their role in the suppression of BLV replication. Microbiol. Immun. 1992, 36, 1317-1323
8. 8 Sugimoto, M., Ohishi, K. and Ikawa, Y. Role of cell-mediated immunity in bovine leukemia virus (BLV) infection in ruminants: its implication for the vaccination strategy against retroviruses. Therapeutic Immun. 1994, 1, 297-301
9. 9 Gregoriadis, G. Liposomes as immunological adjuvants. In: The Theory and Practical Application of Adjuvant (Ed. Stewart-Tull, D.E.S.). John Wiley and Sons Ltd, 1995, pp. 145-169
10. 10 Noguchi, Y., Noguchi, T., Sato, T. et al. Priming for in vitro and in vivo anti-human T lymphotropic virus type I cellular immunity by virus-related protein reconstituted into liposome. J. Immun. 1991, 146, 3599-3603
11. 11 Callebaut, I., Voneche, V., Mager, A. et al. Mapping of B-neutralizing and T-helper cell epitopes on the bovine leukemia virus external glycoprotein gp51. J. Virol. 1993, 67, 5321-5327
12. 12 Sugimoto, M., Ohishi, K., Fukasawa, M. et al. Oligomannosecoated liposomes as an adjuvant for the induction of cell-mediated immunity. FEBS Lett. 1995, 363, 53-56
13. 13 Rice, N.R., Stephens, R.M., Couez, D. et al. The nucleotide sequence of the env gene and post-env region of bovine leukemia virus. Virology 1984, 138, 82-93
14. 14 Sagata, N., Yasunaga, T., Tsuzuku-Kawamura, J., Ohishi, K., Ogawa, Y. and Ikawa, Y. Complete nucleotide sequence of the genome of bovine leukemia virus: its evolutionary relationship to other retroviruses. Proc. Natl Acad. Sci. USA 1985, 82, 677-681
15. 15 Ratner, L., Haseltine, W., Patarca, R. et al. Complete nucleotide sequence of the AIDS virus HTLV-III . Nature 1985, 313, 277-284
16. 16 Mosmann, T.R. and Coffman, R.L. Heterogeneity of cytokine secretion patterns and functions of helper T cells. Adv. Immun. 1989, 46, 111-147
17. 17 Bretscher, P.A., Wei, G., Menon, J.N. and Bielefeldt-Ohmann, H. Establishment of stable, cell-mediated immunity that makes "susceptible" mice resistant to Leishmania major. Science 1992, 257, 539-542
18. 18 Kiderlen, A.F., Kaufmann, S.H.E. and Lohmann-Matthes, M.-L. Protection of mice against the intracellular bacterium Listeria monocytogenes by recombinant immune interferon. Eur. J. Immun. 1984, 14, 964-967
19. 19 Scott, P., Natovitz, P., Coffman, R.L., Pearce, E. and Sher, A. Immunoregulation of cutaneous leishmaniasis: T cell lines that transfer protective immunity or exacerbation belong to different T helper subsets and respond to distinct parasite antigens. J. Exp. Med. 1988, 168, 1675-1684
20. h-2 switch is a critical step in the etiology of HIV infection. Immun. Today 1993, 14, 107-111
21. 21 Salk, J., Bretscher, P.A., Salk, P.L., Clerici, M. and Shearer, G.M. A strategy for prophylactic vaccination against HIV. Science 1993, 260, 1270-1272
22. 22 Jakobson, S., Reuben, J.S., Streilein, R.D. and Palker, T.J. Induction of CD4+, human T lymphotropic virus type-I-specific cytotoxic T lymphocytes from patients with HAM/TSP. J. Virol. 1991, 146, 1155-1162
23. 23 Baba, E., Nakamura, M., Ohkuma, K. et al. Peptide-based human T cell leukemia virus type I vaccine containing T and B cell epitope that induces high titers neutralizing antibodies. J. Immun. 1995, 399-412
24. 24 Takahashi, H., Houghten, R., Putney, S.D. et al. Structural requirements for class I MHC molecule-mediated antigen presentation and cytotoxic T cell recognition of an immunodominant determinant of the human immunodeficiency virus envelope protein. J. Exp. Med. 170, 2023-2035
25. 25 Takeda, A., Tuazon, C.U. and Ennis, F.A. Antibody-enhanced infection by HIV-I via Fc receptor-mediated entry. Science 1988, 242, 580-583
26. 26 Golding, H., Shearer, G.M., Hillman, K. et al. Common epitope in human immunodeficiency virus (HIV) I-gp41 and HLA clas II elicits immunosuppressive autoantibodies capable of contributing to immune dysfunction in HIV I-infected individuals. J. Clin. Invest. 1989, 83, 1430-1433
27. 27 Kannagi, M., Shida, H., Igarashi, H. et al. Target epitope in the tax protein of human T-cell leukemia virus type I recognized by class I major histocompatibility complex-restricted cytotoxic T cells. J. Virol. 1992, 66, 2928-2933
28. 28 Mager, A., Mesengo, R., Mammerickx, M. and Letesson, J.-J. T cell proliferative response to bovine leukaemia virus (BLV): identification of T cell epitopes on the major core protein (p24) in BLV-infected cattle with normal haematological values. J. Gen. Virol. 1994, 75, 2223-2231